CTOs on the Move

CPort Solutions

www.cportsolutions.com

 
CPort Solutions is a Atlanta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 250-1000
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Klox Technologies

Klox Technologies is a Canadian specialty pharmaceutical company focusing on the development and commercialization of its proprietary BioPhotonic technology platform. This non-invasive, pathology-specific topical treatment platform harnesses the power of light and photo activated oxygen-rich gel formulations to target various skin and soft tissue disorders. With franchises in dermatology, wound care, and oral health, Klox Technologies is well positioned to capitalize on significant market opportunities. We believe that our dedication to providing healthcare professionals with novel and effective treatment solutions will allow patients to experience positive results without some of the side effects associated with existing treatments. Klox Technologies’ senior management team has over 80 years of combined experience in the biotechnology, pharmaceutical, and medical devices industries. We continue to research, develop, and commercialize solutions based on our BioPhotonic technology platform for a growing and aging population that is seeking more effective and less invasive treatment options to improve their health and quality of life.

Healthnet Solutions

Healthnet Solutions is a Bloomfield Hills, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Concuity

Concuity is a Vernon Hills, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Stembanc

Stembanc is a Chardon, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Inipharm

At Inipharm, we`re building on novel insights and applying our chemistry expertise to develop therapies for patients with liver disease. Inipharm`s lead program is focused on small-molecules to target the activity of HSD17B13, a highly validated, genetically defined target for multiple severe liver and related diseases.